Lake Street Capital set a $42.00 price objective on Heron Therapeutics (NASDAQ:HRTX) in a research note published on Thursday. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other equities research analysts have also issued reports on HRTX. Noble Financial reissued a buy rating on shares of Heron Therapeutics in a research report on Wednesday, March 21st. BidaskClub lowered Heron Therapeutics from a buy rating to a hold rating in a research report on Wednesday, January 31st. Cantor Fitzgerald set a $40.00 target price on Heron Therapeutics and gave the company a buy rating in a research report on Monday, March 19th. Cowen reissued a buy rating on shares of Heron Therapeutics in a research report on Monday, March 19th. Finally, ValuEngine raised Heron Therapeutics from a sell rating to a hold rating in a research report on Tuesday, March 13th. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $35.92.
NASDAQ:HRTX opened at $26.75 on Thursday. Heron Therapeutics has a fifty-two week low of $12.70 and a fifty-two week high of $32.70.
Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.29). Heron Therapeutics had a negative net margin of 641.87% and a negative return on equity of 230.70%. The business had revenue of $10.05 million for the quarter, compared to the consensus estimate of $9.00 million. sell-side analysts anticipate that Heron Therapeutics will post -2.5 earnings per share for the current year.
In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of the business’s stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $20.00, for a total transaction of $151,680.00. Following the transaction, the vice president now owns 7,584 shares of the company’s stock, valued at approximately $151,680. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kevin C. Tang purchased 192,308 shares of the stock in a transaction on Thursday, March 29th. The shares were bought at an average cost of $26.00 per share, for a total transaction of $5,000,008.00. The disclosure for this purchase can be found here. Insiders have sold a total of 225,584 shares of company stock worth $6,141,680 in the last ninety days. Insiders own 19.93% of the company’s stock.
Large investors have recently bought and sold shares of the business. Ellington Management Group LLC acquired a new position in shares of Heron Therapeutics during the 4th quarter worth approximately $195,000. Pinnacle Associates Ltd. acquired a new position in shares of Heron Therapeutics during the 4th quarter worth approximately $201,000. Trexquant Investment LP acquired a new position in shares of Heron Therapeutics during the 3rd quarter worth approximately $206,000. Jefferies Group LLC acquired a new position in shares of Heron Therapeutics during the 4th quarter worth approximately $214,000. Finally, Jane Street Group LLC acquired a new position in shares of Heron Therapeutics during the 3rd quarter worth approximately $223,000.
TRADEMARK VIOLATION NOTICE: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/08/lake-street-capital-reiterates-42-00-price-target-for-heron-therapeutics-hrtx.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.